LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Inicio・Lista de Acciones・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Cerrado

SectorSanidad

93.25 0.13

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

92.63

Máximo

96.34

Métricas clave
By Trading Economics
Ingresos	-8.1M -56M
Ventas	2.9M 60M
BPA	-0.83
Margen de beneficios	-92.559
Empleados	414
EBITDA	-9.7M -52M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+49.79% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	124M 6B
Apertura anterior	93.12
Cierre anterior	93.25

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

60 / 65.58 Soporte y Resistencia

Rhythm Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 may 2026, 22:44 UTC

Adquisiciones, fusiones, absorciones

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 may 2026, 22:27 UTC

Adquisiciones, fusiones, absorciones

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 may 2026, 22:12 UTC

Ganancias

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 may 2026, 21:52 UTC

Adquisiciones, fusiones, absorciones

LVMH to Sell Marc Jacobs

15 may 2026, 00:00 UTC

Ganancias

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 may 2026, 23:57 UTC

Adquisiciones, fusiones, absorciones

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 may 2026, 23:56 UTC

Adquisiciones, fusiones, absorciones

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 may 2026, 23:56 UTC

Adquisiciones, fusiones, absorciones

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 may 2026, 23:56 UTC

Charlas de Mercado

Gold Prices Rise on Strong Demand -- Market Talk

14 may 2026, 23:56 UTC

Adquisiciones, fusiones, absorciones

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 may 2026, 23:50 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 may 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 may 2026, 23:47 UTC

Ganancias

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 may 2026, 23:47 UTC

Ganancias

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 may 2026, 23:46 UTC

Ganancias

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 may 2026, 23:46 UTC

Ganancias

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 may 2026, 23:28 UTC

Charlas de Mercado

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 may 2026, 23:00 UTC

Charlas de Mercado

Australia's One Nation Party Leads In The Polls -- Market Talk

14 may 2026, 22:46 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 may 2026, 22:46 UTC

Charlas de Mercado

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 may 2026, 22:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 may 2026, 22:35 UTC

Charlas de Mercado

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 may 2026, 22:11 UTC

Adquisiciones, fusiones, absorciones

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 may 2026, 22:06 UTC

Charlas de Mercado

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 may 2026, 22:04 UTC

Ganancias

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 may 2026, 22:04 UTC

Ganancias

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 may 2026, 22:04 UTC

Ganancias

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 may 2026, 22:00 UTC

Ganancias

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 may 2026, 21:55 UTC

Ganancias

Nu Holdings 1Q EPS 18c >NU

14 may 2026, 21:55 UTC

Ganancias

Nu Holdings 1Q Rev $4.97B >NU

Comparación entre iguales

Cambio de precio

Rhythm Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

49.79% repunte

Estimación a 12 Meses

Media 136.77 USD 49.79%

Máximo 158 USD

Mínimo 105 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

Comprar

Mantener

Vender

De acuerdo con 14 analistas que ofrecen calificaciones bursátiles a para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

60 / 65.58Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.